Drug Profile

P-ESBP-DOX

Latest Information Update: 21 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ben Gurion University
Developer Vaxil BioTherapeutics
Class Anthracyclines; Antineoplastics; Peptide drug conjugates; Peptides; Polymers
Mechanism of Action DNA inhibitors; Type II DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer

Highest Development Phases

Preclinical Cancer

Most Recent Events

12 Jan 2022 P-ESBP-DOX is available for licensing as of 12 Jan 2022. https://vaxil-bio.com/vaxil-immunotherapy-pipeline/#propertyright
12 Jan 2022 Vaxil Biotherapeutics has patent protection for VaxHit™ platform (Vaxil Biotherapeutics pipeline, January 2022)
12 Jan 2022 Preclinical trials in Cancer in Israel (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com